Driven by its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Watchmaker Genomics
5 followers
Discovery Life Sciences
3 followers
Mineralys Therapeutics
3 followers
Neuron23
3 followers
Enveda Biosciences
2 followers
CG Oncology
2 followers
Ultima Genomics
6 followers
Cogent Biosciences
1 follower
Priovant
4 followers
Cytovale
1 follower
Immunic Therapeutics
1 follower
Araceli Biosciences
1 follower